Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Southwest Airlines Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $291.85 (market cap $39.89B), while Southwest Airlines Co trades at $48.38 (market cap $23.67B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Southwest Airlines Co pays a 1.49% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LUV | |
|---|---|---|
Market Cap | $39.89B | $23.67B |
Sector | Health | Industrials |
52-Week High | $491.22 | $54.80 |
52-Week Low | $278.09 | $29.06 |
Enterprise Value | $38.15B | $26.74B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Southwest Airlines (LUV) trades at $48.43, down 1.61% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported mixed Q1 2026 earnings, missing estimates, but maintains a positive outlook with Q2 2026 EPS expected at $0.52. Recent news highlights sector tailwinds from lower fuel costs and a partnership with AWS to accelerate AI capabilities by 2028.
LUV presents a balanced risk-reward profile with a consensus price target of $52.47, offering ~8% upside. Key opportunities include earnings growth potential and favorable industry dynamics, while risks involve Boeing 737 MAX incidents and volatile fuel prices. Analyst sentiment is mixed, with 42% buy ratings, reflecting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
